Current status of cetuximab for the treatment of patients with solid tumors

Annals of Pharmacotherapy

Volumn 40, Issue 2, 2006, Pages 241-250

  Frieze, Deborah A ^a,b   McCune, Jeannine S ^b,c  

^a SEATTLE CANCER CARE ALLIANCE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Cetuximab; Colorectal cancer; Non small cell lung cancer

Indexed keywords

ADRENALIN; ANTIBIOTIC AGENT; ANTIHISTAMINIC AGENT; BEVACIZUMAB; CAPECITABINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; CORTICOSTEROID; DEXAMETHASONE; DIPHENHYDRAMINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEFITINIB; GEMCITABINE; HISTAMINE H1 RECEPTOR ANTAGONIST; IRINOTECAN; MONOCLONAL ANTIBODY; NAVELBINE; OXALIPLATIN; PACLITAXEL; PEMETREXED; PLATINUM DERIVATIVE; PROTEIN TYROSINE KINASE INHIBITOR; TAXANE DERIVATIVE; VASCULOTROPIN INHIBITOR;

ABDOMINAL PAIN; ACNE; AIRWAY OBSTRUCTION; ANAPHYLAXIS; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CHILL; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST BENEFIT ANALYSIS; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRY SKIN; DYSPNEA; EVIDENCE BASED MEDICINE; FATIGUE; FEVER; FOLLICULITIS; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPOMAGNESEMIA; HYPOTENSION; INFECTION; INTERSTITIAL LUNG DISEASE; KIDNEY FAILURE; LUNG EMBOLISM; LUNG NON SMALL CELL CANCER; MALAISE; MEDICAL LITERATURE; METASTASIS; MONOTHERAPY; NAUSEA; NEUTROPENIA; NONHUMAN; PARONYCHIA; PRACTICE GUIDELINE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; REVIEW; SEPSIS; SKIN MANIFESTATION; SKIN TOXICITY; SOLID TUMOR; SURVIVAL RATE; THROMBOCYTOPENIA; URTICARIA;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS; HUMANS; NEOPLASMS; TREATMENT OUTCOME;

EID: 33144486481     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1G191     Document Type: Review

References (68)

1. Grunwald V, Hidalgo M. Developing inhibitors of the epidermal growth factor receptor for cancer treatment. J Natl Cancer Inst 2003;95:851-67.
2. Herbst RS. Review of epidermal growth factor receptor biology. Int J Radiat Oncol Biol Phys 2004;59:21-6. DOI 10.1016/j.ijrobp.2003.11.041
3. Yarden Y. The EGFR family and its ligands in human cancer. Signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001;37(suppl 4):S3-8.
4. Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell 2000;103:211-25. DOI 10.1016/S0092-8674(00)00114-8
5. Starling N, Cunningham D. Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions. Curr Opin Oncol 2004;16:385-90. DOI 10.1097/01.cco.0000128278.15371.e4
6. Shin DM, Donate NJ, Perez-Soler R, et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res 2001;7:1204-13
7. Baselga J, Pfister D, Cooper MR, et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol 2000;18:904-14.
8. Prewett MC, Hooper AT, Bassi R, ElHs LM, Waksal HW, Hicklin DJ. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts. Clin Cancer Res 2002;8:994-1003
9. Ciardiello F, Bianco R, Damiano V, et al. Antitumor activity of sequential treatment with topotecan and anti-epidermal growth factor receptor monoclonal antibody C225. Clin Cancer Res 1999;5:909-16.
10. Castillo L, Etienne-Grimaldi MC, Fischel JL, Formento P, Magne N, Milano G. Pharmacological background of EGFR targeting. Ann Oncol 2004;15:1007-12. DOI 10.1093/annonc/mdh257
11. Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer. J Clin Oncol 2003;21:2787-99. DOI 10.1200/JCO.2003.01.504
12. Mendelsohn J. Targeting the epidermal growth factor receptor for cancer therapy. J Clin Oncol 2002;20(18 suppl):1s-13s.
13. Rubin EH, Doroshow J, Hidalgo M, et al. A study to assess the pharmacokinetics of cetuximab (abstract 3084). Proc Am Soc Clin Oncol 2004;23:216.
14. Package insert. Erbitux (cetuximab). Branchburg, NJ: ImClone Systems and Bristol-Myers Squibb, June 2004.
15. Fox FE, Mauro D, Bai S, et al. A population pharmacokinetic analysis of the anti-EGFR specific IgG1 monoclonal antibody cetuximab (abstract 290). Presented at: American Society of Clinical Oncology Gastrointestinal Cancers Symposia, San Francisco, January 22-24, 2004.
16. Resell R, Fossella F, Milas L. Molecular markers and targeted therapy with novel agents: prospects in the treatment of non-small cell lung cancer. Lung Cancer 2002;38(suppl 4):43-9. DOI 10.1016/S0169-5002(02)00171-X
17. Robert F, Ezekiel MP, Spencer SA, et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol 2001;19:3234-43.
18. Jemal A, Murray T, Ward E, et al. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
19. Penland SK, Goldberg RM. Current strategies in previously untreated advanced colorectal cancer. Oncology (Huntingt) 2004;18:715-22, 727; discussion 27-9.
20. Engstrom PF. NCCN clinical practice guidelines in oncology-colon cancer. Last update. www.nccn.org/professionals/physician_gls/default.asp (accessed 2005 Jun 11).
21. New treatments for colorectal cancer. FDA Consumer 2004;38. www.fda.gov/fdac/features/2004/304_cancer.html (accessed 2006 Jan 2).
22. Saltz LB, Meropol NJ, Loehter PJ Sr, Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-8. DOI 10.1200/JCO.2004.10.182
23. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-45. DOI 10.1056/NEJMoa033025
24. National Cancer Institute. Clinical trials search, www.cancer.gov/ clinical-trials (accessed 2005 Dec 27).
25. Badarinath S, Mitchell EP, Jennis A, et al. Cetuximab plus FOLFOX for colorectal cancer (EXPLORE): preliminary safety analysis of a randomized phase III trial (abstract 3531). Proc Am Soc Clin Oncol 2004;23:253.
26. Tabernero JM, Van Cutsem E, Sastre J, et al. An international phase II study of cetuximab in combination with oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) in the first-line treatment of patients with metastatic colorectal cancer (CRC) expressing epidermal growth factor receptor (EGFR). Preliminary results (abstract 3512). Proc Am Soc Clin Oncol 2004;23:248.
27. Forastiere A. NCCN clinical practice guidelines in oncology-head & neck cancers. Last update v1.2006. www.nccn.org/professionals/physician_gls/ default.asp (accessed 2005 Dec 27).
28. Song J, Chen C, Raben D. Emerging role of EGFR-targeted therapies and radiation in head and neck cancer. Oncology (Huntingt) 2004;18:1757-67; discussion 67,71-2,77.
29. Trigo T, Hitt R, Koralewski P, Diaz-Rubio E, Rolland R, Knecht R, et al. Cetuximab monotherapy is active in patients with platinum-refractory recurrent metastatic squamous cell carcinoma of the head and neck (SC-CHN): results of a phase II study (abstract 5502). Proc Am Soc Clin Oncol 2004;23:487.
30. Yokes EE. Clinical trials of cetuximab in SCCHN. Clin Advance Hematol Oncol 2004;2:6-7.
31. Baselga J, Trigo JM, Bourhis J, et al. Phase II multicenter study of the antiepidermal growth factor receptor monoclonal antibody cetuximab in combination with platinum-based chemotherapy in patients with platinum-refractory metastatic and/or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol 2005:23:5568-77.
32. Herbst RS, Arquette M, Shin DM, et al. Phase II multicenter study of the epidermal growth factor receptor antibody cetuximab and cisplatin for recurrent and refractory squamous cell carcinoma of the head and neck. J Clin Oncol 2005;23:5578-87.
33. Burtness B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 2005;23:8646-54. DOI 10.1200/JCO.2005.02.4646
34. Burtness B. Cetuximab and cisplatin for chemotherapy-refractory squamous cell cancer of the head and neck. J Clin Oncol 2005;23:5440-2.
35. Bonner JA, Giralt J, Harari PM, et al. Cetuximab prolongs survival in patients with locoregionally advanced squamous cell carcinoma of head and neck: a phase III study of high dose radiation therapy with or without cetuximab (abstract 5507). Proc Am Soc Clin Oncol 2004;23:248.
36. Su YB, Kraus DH, Lis E, et al. Concurrent cetuximab, cisplatin, and concomitant boost radiation therapy (RT) for locoregionally advanced, squamous cell head and neck cancer (SCCHN): preliminary evaluation of a new combined-modality paradigm (abstract 5529). Proc Am Soc Clin Oncol 2005;24:495.
37. Amann J, Kalyankrishna S, Massion PP, et al. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res 2005;65:226-35.
38. Package insert. Tarceva (erlotinib). Melville, NJ: OSI Pharmaceuticals and Genentech, 2004.
39. Lynch TJ, Lilenbaum RC, Bonomi P, et al. A phase II trial of cetuximab as therapy for recurrent non-small cell lung cancer (NSCLC) (abstract 7084). Proc Am Soc Clin Oncol 2004;23:634.
40. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
41. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group. J Clin Oncol 2000;18:2354-62.
42. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97. DOI 10.1200/JCO.2004.08.163
43. Kim ES, Mauer AM, Tran HT, et al. A phase II study of cetuxirnab, an epidermal growth factor receptor (EGFR) blocking antibody, in combination with docetaxel chemotherapy refractory/resistant patients with advanced non-small cell lung cancer (abstract 2581). Proc Am Soc Clin Oncol 2003;22:642.
44. Ettinger DS. NCCN clinical practice guidelines in oncology-Non-small cell lung cancer. Last update V2.2006. www.nccn.org/professionals/physician_gls/ default.asp (accessed 2005 Dec 27).
45. Pfister DG, Johnson DH, Azzoli CG, et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003. J Clin Oncol 2004;22:330-53. DOI 10.1200/JCO.2004.09.053
46. Schiller JH, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 2002;346:92-8. DOI 10.1056/NEJMoa011954
47. Thienelt CD, Bunn PA Jr, Hanna N, et al. Multicenter phase I/II study of cetuxirnab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 2005;23:8786-93. DOI 10.1200/JCO.2005.03.1997
48. Robert F, Blumenschein G, Herbst RS, et al. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapynaïve advanced non-small-cell lung cancer. J Clin Oncol 2005;23:9089-96. DOI 10.1200/JC0.2004.00.1438
49. Resell R, Daniel C, Ramlau R, el al. Randomized phase II study of cetuximab in combination with cisplalin (C) and vinorelbine (V) vs. CV alone in the first-line treatment of patients with epidermal growth factor receptor (EGFR)-expressing advanced non-small-cell lung cancer (abstract 7012). Proc Am Soc Clin Oncol 2004;23:618.
50. Socinski MA. Clinical trials of cetuximab in NSCLC. Clin Adv Hematol Oncol 2004;2:4-5.
51. Gandara DR, West H, Chansky K, et al. Bronchioloalveolar carcinoma: a model for investigating the biology of epidermal growth factor receptor inhibition. Clin Cancer Res 2004;10:4205s-9s
52. Xiong HQ, Rosenberg A, LoBuglio A, et al. Cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor, in combination with gemcitabine for advanced pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2004;22:2610-6. DOI 10.1200/JCO.2004.12.040
53. Kurtz JE, Negrier S, Husseini F, et al. A phase II study of docetaxelirinotecan combination in advanced pancreatic cancer. Hepatogastroenterology 2003;50:567-70.
54. Busam KJ, Capodieci P, Motzer R, Kiehn T, Phelan D, Halpern AC. Cutaneous side-effects in cancer patients treated with the antiepidermal growth factor receptor antibody C225. Br J Dermatol 2001;144:1169-76. DOI 10.1046/j.1365-2133. 2001.04226.x
55. Carson EJ, Novak AM, Stella PJ. Hypomagnesemia in patients with stage IV colorectal cancer treated with cetuximab as a single agent (abstract 3655). Proc Am Soc Clin Oncol 2005;24:248.
56. Gridelli C, Massarelli E, Maione P, et al. Potential role of molecularly targeted therapy in the management of advanced nonsmall cell lung carcinoma in the elderly. Cancer 2004;101:1733-44. DOI 10.1002/cncr.20572
57. Lenz HJ, Mayer RJ, Gold PJ, et al. Activity of cetuximab in patients with colorectal cancer refractory to both irinotecan and oxaliplatin (abstract 3510). Proc Am Soc Clin Oncol 2004;23:248.
58. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colocrectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-10. DOI 10.120Q/JCO.2005.08.037
59. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Storkel S. Immunohistochemical detection of EGFR in paraffin-embedded tumor tissues: variation in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 2004;52:893-901. DOI 10.1369/jhc.3A6195. 2004
60. Scartozzi M, Bearzi I, Berardi R, Mandolesi A, Fabris G, Cascinu S. Epidermal growth factor receptor (EGFR) status in primary colorectal tumors does not correlate with EGFR expression in related metastatic sites: implications for treatment with EGFR-targeted monoclonal antibodies. J Clin Oncol 2004;22:4772-8. DOI 10.1200/JCO.2004.00.117
61. Amador ML, Oppenheimer D, Perea S, et al. An epidermal growth factor receptor intron 1 polymorphism mediates response to epidermal growth factor receptor inhibitors. Cancer Res 2004;64:9139-43.
62. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004;64:8919-23.
63. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-39. DOI 10.1056/NFJMoa040938
64. Zhang W, Yun J, Press OA, et al. Association of cyclin D1 (CCND1) gene A870G polymorphism and clinical outcome of EGFR-positive metastatic colorectal cancer patients treated with epidermal growth factor receptor (EGFR) inhibitor cetuximab (C225) (abstract 3518). Proc Am Soc Clin Oncol 2004;23:250.
65. Baselga J. Skin as a surrogate tissue for pharmacodynamic end points: is it deep enough? Clin Cancer Res 2003;9:2389-90.
66. Ciardiello F, Bianco R, Caputo R, et al. Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 2004;10:784-93.
67. 2005 Redbook. Montvale, NJ: Thompson PDR: 371, 624.
68. Schrag D. The price tag on progress-chemotherapy for colorectal cancer. N Engl J Med 2004;351:317-9.